Last reviewed · How we verify
VIS410
At a glance
| Generic name | VIS410 |
|---|---|
| Sponsor | Visterra, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A (PHASE2)
- Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A (PHASE2)
- Influenza Challenge Study of VIS410 in Healthy Volunteers (PHASE2)
- A Study of VIS410 to Assess Safety and Pharmacokinetics (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VIS410 CI brief — competitive landscape report
- VIS410 updates RSS · CI watch RSS
- Visterra, Inc. portfolio CI